Pierre Fabre gets EC approval for BRAFTOVI plus Cetuximab to treat bowel cancer
The regulatory approval is based on the Phase 3 BEACON CRC trial, which showed positive results for BRAFTOVI…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Jun 20
The regulatory approval is based on the Phase 3 BEACON CRC trial, which showed positive results for BRAFTOVI…
04 Jun 20
NVX-CoV2373 is a stable, prefusion protein designed by Novavax, leveraging its original nanoparticle technology, to work against SARS-CoV-2…
03 Jun 20
CFI-402411 is a potential HPK1 inhibitor that has demonstrated immune-activating effects and cytotoxic effects in preclinical studies
03 Jun 20
Philips’ new patient monitoring solutions will support infection-control protocols and remotely provide critical patient information for caregivers
02 Jun 20
The study is a randomised, placebo-controlled, double-blind Phase 1 clinical trial that evaluates the safety, tolerability of LY-CoV555
02 Jun 20
The new indication expands Brilinta treatment to high-risk coronary patients without a history of stroke or heart attack
01 Jun 20
Janssen’s investigational Ebola vaccine regimen leverages its AdVac and PER.C6 technologies and Bavarian Nordic’s MVA-BN technology
01 Jun 20
Tecentriq plus Avastin is the only cancer immunotherapy regimen approved for the treatment of metastatic hepatocellular carcinoma
29 May 20
FDA indicated TAUVID for PET imaging of brain to assess the density and distribution of NFTs in patients…
28 May 20
With the EC approval, Zeposia becomes the only approved S1P receptor modulator available for the treatment of RRMS…